旗下有三精/哈藥/蓋中蓋/胃必治/護彤/世一堂等多個享譽市場的品牌,主營抗生素/非處方藥及保健品/傳統與現代中藥/生物醫藥/動物疫苗及醫藥商業等
哈(ha)(ha)(ha)藥集(ji)團有(you)(you)(you)限(xian)公(gong)(gong)司(si)(si)(si)(以(yi)下簡稱“哈(ha)(ha)(ha)藥集(ji)團”)為中(zhong)外(wai)合(he)資(zi)(zi)(zi)(zi)企(qi)(qi)業(ye)(ye)。哈(ha)(ha)(ha)爾濱市國(guo)(guo)資(zi)(zi)(zi)(zi)委(wei)持(chi)(chi)(chi)股(gu)(gu)(gu)38.25%,中(zhong)信資(zi)(zi)(zi)(zi)本冰島投(tou)資(zi)(zi)(zi)(zi)有(you)(you)(you)限(xian)公(gong)(gong)司(si)(si)(si)持(chi)(chi)(chi)股(gu)(gu)(gu)19.1%,華平冰島投(tou)資(zi)(zi)(zi)(zi)有(you)(you)(you)限(xian)公(gong)(gong)司(si)(si)(si)持(chi)(chi)(chi)股(gu)(gu)(gu)18.7%,哈(ha)(ha)(ha)爾濱國(guo)(guo)企(qi)(qi)重(zhong)組管(guan)理顧問有(you)(you)(you)限(xian)公(gong)(gong)司(si)(si)(si)持(chi)(chi)(chi)股(gu)(gu)(gu)8.5%,重(zhong)慶哈(ha)(ha)(ha)珀(po)股(gu)(gu)(gu)權投(tou)資(zi)(zi)(zi)(zi)基金合(he)伙企(qi)(qi)業(ye)(ye)(有(you)(you)(you)限(xian)合(he)伙)持(chi)(chi)(chi)股(gu)(gu)(gu)10%,天津黑馬(ma)祺航投(tou)資(zi)(zi)(zi)(zi)管(guan)理有(you)(you)(you)限(xian)公(gong)(gong)司(si)(si)(si)持(chi)(chi)(chi)股(gu)(gu)(gu)5%,黑龍江中(zhong)信資(zi)(zi)(zi)(zi)本醫(yi)藥產(chan)業(ye)(ye)股(gu)(gu)(gu)權投(tou)資(zi)(zi)(zi)(zi)合(he)伙企(qi)(qi)業(ye)(ye)(有(you)(you)(you)限(xian)合(he)伙)持(chi)(chi)(chi)股(gu)(gu)(gu)0.425%。旗(qi)下擁(yong)有(you)(you)(you)哈(ha)(ha)(ha)藥股(gu)(gu)(gu)份(fen)(fen),人(ren)民同(tong)泰兩(liang)家上市公(gong)(gong)司(si)(si)(si)(截至2019年6月30日,哈(ha)(ha)(ha)藥集(ji)團持(chi)(chi)(chi)有(you)(you)(you)哈(ha)(ha)(ha)藥股(gu)(gu)(gu)份(fen)(fen)46.49%股(gu)(gu)(gu)權,哈(ha)(ha)(ha)藥股(gu)(gu)(gu)份(fen)(fen)持(chi)(chi)(chi)有(you)(you)(you)人(ren)民同(tong)泰74.82%股(gu)(gu)(gu)權)。旗(qi)下哈(ha)(ha)(ha)藥股(gu)(gu)(gu)份(fen)(fen)于2018年9月投(tou)資(zi)(zi)(zi)(zi)3億美元認購(gou)了(le)美國(guo)(guo)保健品(pin)GNC發(fa)行的可(ke)轉(zhuan)(zhuan)換優先股(gu)(gu)(gu),轉(zhuan)(zhuan)股(gu)(gu)(gu)完成(cheng)后(hou),將(jiang)持(chi)(chi)(chi)有(you)(you)(you)GNC40.1%股(gu)(gu)(gu)權,成(cheng)為其單一大股(gu)(gu)(gu)東。
集團擁有哈(ha)(ha)藥(yao)(yao)(yao)總(zong)廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)三(san)精(jing)、哈(ha)(ha)藥(yao)(yao)(yao)六(liu)廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)中藥(yao)(yao)(yao)二廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)世一堂、哈(ha)(ha)藥(yao)(yao)(yao)生物、哈(ha)(ha)藥(yao)(yao)(yao)三(san)精(jing)四廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)三(san)精(jing)明水、哈(ha)(ha)藥(yao)(yao)(yao)三(san)精(jing)千鶴、哈(ha)(ha)藥(yao)(yao)(yao)三(san)精(jing)兒童、哈(ha)(ha)藥(yao)(yao)(yao)疫苗(miao)等(deng)11家(jia)工業(ye)企業(ye)和(he)哈(ha)(ha)藥(yao)(yao)(yao)人民同(tong)泰、哈(ha)(ha)藥(yao)(yao)(yao)營銷(xiao)有限公司(si)2家(jia)商業(ye)流通企業(ye)及1家(jia)藥(yao)(yao)(yao)物研(yan)究(jiu)院(yuan)。
集團主營(ying)涵蓋(gai)抗生素、非處方藥(yao)及保(bao)健品(pin)、傳統與(yu)現代(dai)中藥(yao)、生物醫藥(yao)、動物疫(yi)苗(miao)及醫藥(yao)商業六(liu)大業務(wu)板塊。哈藥(yao)股份有(you)1816個藥(yao)品(pin)批(pi)文和(he)74個保(bao)健食品(pin)批(pi)文。主導產品(pin)有(you)葡萄糖酸(suan)(suan)鈣口(kou)服(fu)(fu)溶液、葡萄糖酸(suan)(suan)鋅(xin)口(kou)服(fu)(fu)溶液、阿莫(mo)西林膠囊(nang)、雙黃連口(kou)服(fu)(fu)液、前列地爾注(zhu)射(she)液、小兒氨酚黃那敏顆粒、拉西地平片、注(zhu)射(she)用鹽酸(suan)(suan)頭孢替安(an)、布洛芬顆粒、新蓋(gai)中蓋(gai)牌高鈣片等。截(jie)至2018年(nian)底,具備年(nian)產原(yuan)料藥(yao)2200噸、化藥(yao)注(zhu)射(she)劑(ji)(ji)9.8億支、中藥(yao)注(zhu)射(she)劑(ji)(ji)1.8億支、口(kou)服(fu)(fu)液20億支、片劑(ji)(ji)120億片、膠囊(nang)131億粒、化藥(yao)顆粒劑(ji)(ji)12億袋的生產能(neng)力。
所屬上(shang)市(shi)公司(si)人(ren)民(min)(min)同(tong)泰主營醫(yi)藥(yao)批(pi)發和零(ling)(ling)售(shou)業(ye)(ye)(ye)務(wu)(wu)(wu),涵蓋中(zhong)成藥(yao)、中(zhong)藥(yao)飲片、化學藥(yao)制劑、抗生(sheng)素、生(sheng)物(wu)制品、生(sheng)化藥(yao)品、醫(yi)療器械及保(bao)健品等(deng)萬余(yu)個品規(gui)。有(you)人(ren)民(min)(min)同(tong)泰醫(yi)藥(yao)連鎖店314家(jia),年(nian)(nian)營業(ye)(ye)(ye)額(e)11.5億元(yuan)。其下(xia)屬藥(yao)品批(pi)發企(qi)業(ye)(ye)(ye)與黑龍江(jiang)省內1000多(duo)家(jia)醫(yi)療機構,1900多(duo)家(jia)第三(san)終端(duan),近700家(jia)商業(ye)(ye)(ye)客戶開展緊密合作,三(san)級以上(shang)醫(yi)院的(de)(de)市(shi)場覆蓋率95%以上(shang),二級以上(shang)醫(yi)院的(de)(de)市(shi)場覆蓋率達90%以上(shang)。其物(wu)流(liu)配(pei)送中(zhong)心(xin)(xin)是黑龍江(jiang)省、東北(bei)地(di)區較大的(de)(de)現(xian)代化醫(yi)藥(yao)物(wu)流(liu)中(zhong)心(xin)(xin),儲存能(neng)力40萬箱,年(nian)(nian)吞吐能(neng)力300億元(yuan)。根(gen)據商務(wu)(wu)(wu)部發布(bu)的(de)(de)《2018年(nian)(nian)藥(yao)品流(liu)通行(xing)業(ye)(ye)(ye)運行(xing)統計分析報告(gao)》顯示,2018年(nian)(nian)人(ren)民(min)(min)同(tong)泰批(pi)發業(ye)(ye)(ye)務(wu)(wu)(wu)收入在全(quan)國(guo)藥(yao)品批(pi)發企(qi)業(ye)(ye)(ye)中(zhong)排行(xing)第27位,零(ling)(ling)售(shou)業(ye)(ye)(ye)務(wu)(wu)(wu)銷售(shou)總額(e)在全(quan)國(guo)零(ling)(ling)售(shou)企(qi)業(ye)(ye)(ye)中(zhong)排行(xing)第23位。
集(ji)團(tuan)還擁(yong)有占地面積(ji)4萬(wan)平(ping)方米,建筑(zhu)面積(ji)3.8萬(wan)平(ping)方米的新藥(yao)(yao)研發(fa)基(ji)地——哈藥(yao)(yao)集(ji)團(tuan)技術中心(xin),下設生物(wu)藥(yao)(yao)、化學原料(liao)藥(yao)(yao)、化學制劑、保(bao)健食(shi)品(pin)、質量(liang)檢測分析(xi)5個研發(fa)平(ping)臺(tai),擁(yong)有發(fa)明(ming)授(shou)權專(zhuan)利25件(jian),近5年獲得生產批件(jian)6個,臨(lin)床批件(jian)17個。
截(jie)至2018年末,哈藥集團在職員(yuan)(yuan)工總數18618人(ren)。其中(zhong),正式(shi)員(yuan)(yuan)工15968人(ren),臨時用工人(ren)員(yuan)(yuan)2650人(ren)。擁有(you)中(zhong)級(ji)以(yi)上職稱的3245人(ren),占正式(shi)員(yuan)(yuan)工的20%;大學(xue)本科以(yi)上學(xue)歷的4916人(ren),占正式(shi)員(yuan)(yuan)工的31%,其中(zhong)博士研(yan)究生11人(ren),碩士研(yan)究生398人(ren)。
2018年,哈藥(yao)集團資(zi)產總(zong)(zong)額143.65億(yi)元(yuan)(yuan)(yuan);固定資(zi)產35.63億(yi)元(yuan)(yuan)(yuan);凈資(zi)產83.03億(yi)元(yuan)(yuan)(yuan);實現(xian)營業收入111.63億(yi)元(yuan)(yuan)(yuan);利潤(run)總(zong)(zong)額6.36億(yi)元(yuan)(yuan)(yuan);凈利潤(run)4.40億(yi)元(yuan)(yuan)(yuan),利稅13.11億(yi)元(yuan)(yuan)(yuan)。